Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Bronx, NY
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
New York, NY
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Orchard Park, NY
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orchard Park, NY
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Rochester, NY
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Roslyn, NY
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Roslyn, NY
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Smithtown, NY
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Smithtown, NY
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Syracuse, NY
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Asheville, NC
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Chapel Hill, NC
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Charlotte, NC
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Monroe, NC
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Monroe, NC
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Wilmington, NC
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Columbus, OH
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Dayton, OH
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Fairfield, OH
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fairfield, OH
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Mayfield, OH
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
mi
from
Mayfield, OH
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Oklahoma City, OK
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Erie, PA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Erie, PA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Philadelphia, PA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Pittsburgh, PA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
West Reading, PA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
West Reading, PA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Wexford, PA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wexford, PA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Charleston, SC
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Jackson, TN
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jackson, TN
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Amarillo, TX
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Austin, TX
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Dallas, TX
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Fort Worth, TX
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Houston, TX
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Lubbock, TX
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
San Antonio, TX
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Sugar Land, TX
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sugar Land, TX
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Salt Lake City, UT
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Newport News, VA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newport News, VA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Richmond, VA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Spokane, WA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Tacoma, WA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Yakima, WA
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Yakima, WA
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Clarksburg, WV
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Clarksburg, WV
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Glendale, WI
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, WI
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Milwaukee, WI
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Monroe, WI
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Monroe, WI
Click here to add this to my saved trials
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated:  12/31/1969
mi
from
Edmonton,
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status: Enrolling
Updated: 12/31/1969
mi
from
Edmonton,
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated:  12/31/1969
mi
from
Huntsville, AL
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated:  12/31/1969
mi
from
Paradise Valley, AZ
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated:  12/31/1969
mi
from
Tucson, AZ
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated:  12/31/1969
mi
from
Little Rock, AR
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated:  12/31/1969
mi
from
Huntington Beach, CA
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated:  12/31/1969
mi
from
La Jolla, CA
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated:  12/31/1969
mi
from
Los Angeles, CA
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials